Glenn Hunzinger, PwC's US Health Industries Leader, speaks with James Woods, PwC's US MedTech Leader, about the forces shaping MedTech dealmaking in 2026. Despite capital market pressures, supply chain challenges, and geopolitical uncertainty, companies continue to invest in innovation, portfolio transformation, and growth opportunities. The conversation explores where capital is flowing, how companies are reshaping portfolios, and what dealmakers should watch in the months ahead.

Discussion highlights:

• Continued MedTech deal activity despite capital market pressures and economic uncertainty
• Investment focused on cardiovascular technologies, robotics, connected care, and ecosystem-enabling solutions
• Portfolio transformation as a driver of growth, shareholder value, and strategic repositioning
• Connected care's role in improving efficiency, patient outcomes, and healthcare delivery
• Private equity activity across take-private transactions and portfolio carve-outs
• Strategic priorities for MedTech leaders balancing organic growth, M&A, and capital allocation

Speakers:
Glenn Hunzinger, US Health Industries Leader, PwC
James Woods, US MedTech Deals Leader, PwC

For additional insights on the medtech deals landscape, check out our Medtech: US Deals 2026 midyear outlook https://www.pwc.com/us/en/industries/health-industries/library/medtech-deals-outlook.html

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.